Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Bemotrizinol Photoallergic Potential
NCT05254912Phase 2Completed
- Sponsor
- DSM-Firmenich
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of bemcentinib in sunburn (3 arms), sponsored by DSM-Firmenich. Primary endpoints: Photoallergy potential of a BEMT (6%) formulation based on a dermal scoring system 24 hours post irradiation, Photoallergy potential of a BEMT (6%) formulation based on a dermal scoring system 48 hours post irradiation and 1 more. Started Mar 2022; status: completed.
02
Drugs
bemcentinib
03
Conditions
sunburn
Beyond the preview
Go deeper on NCT05254912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254912.